Surromed Inc. and Applied Biosystems Awarded Grant To Develop New Technology
Mountain View, CA and Foster City, CA, October 16, 2001 / PRNewswire/ SurroMed, Inc. and Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, today announced that they have been awarded a three-year, $8 million grant from the National Institute of Standards and Technology (NIST) Advanced Technology Program (ATP). The grant is for the development of SurroMed's nanoscale technology and Applied Biosystems' multiplexing chemistry capabilities for DNA analysis. SurroMed expects to receive approximately $3.7 million of such funding, and Applied Biosystems expects to receive approximately $4.3 million.
NIST is a non-regulatory federal agency within the U.S. Commerce Department's Technology Administration that promotes measurement, standards, and technology to enhance productivity, facilitate trade and improve the quality of life. NIST-ATP awards are intended to accelerate the development of innovative technologies for broad national benefit through research and development partnerships with the private sector. NIST-ATP awards are granted on the basis of a rigorous competitive review that considers the scientific and technical merit of each proposal and the potential benefits to the U.S. economy. More information on the NIST-ATP award may be obtained at www.atp.nist.gov.
"We are pleased to receive the NIST-ATP grant to develop our novel technology with the chemistry development capabilities of Applied Biosystems," said Gordon Ringold, Ph.D., Chairman and CEO of SurroMed. "We are developing the technology for use in our discovery programs, and the collaboration with Applied Biosystems reflects our strategy to partner certain applications with leading companies."
"Applied Biosystems is pleased to be a recipient of the NIST-ATP award with SurroMed," said Michael Albin, Ph.D., Vice President, Science and Technology of Applied Biosystems. "We look forward to the possibility of integrating Applied Biosystems' strengths in chemistry with SurroMed's technology."
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
About the Applied Biosystems Group
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins to make scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation therapeutic discovery business. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for its own internal product development and for its customers, including collaboration partners and subscribers. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the worldwide web at www.applera.com or by phoning 1-800-762-6923.
For Applied Biosystems: Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe" or "expect" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Applied Biosystems businesses include but are not limited to (1) rapidly changing technology; (2) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.
Contacts:
SurroMed, Inc. Noonan/Russo Communications, Inc.
August J. Moretti Ian McConnell, Ph.D
CFO and General Counsel Senior Account Executive
(650) 230-1564 (415) 677-4455 ext. 233
email: [email protected] email :[email protected]
Applied Biosystems
Media Investors
Lori Murray Peter Dworkin
(650) 638-6130 (650) 554-2479
[email protected] [email protected]
NIST is a non-regulatory federal agency within the U.S. Commerce Department's Technology Administration that promotes measurement, standards, and technology to enhance productivity, facilitate trade and improve the quality of life. NIST-ATP awards are intended to accelerate the development of innovative technologies for broad national benefit through research and development partnerships with the private sector. NIST-ATP awards are granted on the basis of a rigorous competitive review that considers the scientific and technical merit of each proposal and the potential benefits to the U.S. economy. More information on the NIST-ATP award may be obtained at www.atp.nist.gov.
"We are pleased to receive the NIST-ATP grant to develop our novel technology with the chemistry development capabilities of Applied Biosystems," said Gordon Ringold, Ph.D., Chairman and CEO of SurroMed. "We are developing the technology for use in our discovery programs, and the collaboration with Applied Biosystems reflects our strategy to partner certain applications with leading companies."
"Applied Biosystems is pleased to be a recipient of the NIST-ATP award with SurroMed," said Michael Albin, Ph.D., Vice President, Science and Technology of Applied Biosystems. "We look forward to the possibility of integrating Applied Biosystems' strengths in chemistry with SurroMed's technology."
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
About the Applied Biosystems Group
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins to make scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation therapeutic discovery business. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for its own internal product development and for its customers, including collaboration partners and subscribers. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the worldwide web at www.applera.com or by phoning 1-800-762-6923.
For Applied Biosystems: Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe" or "expect" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Applied Biosystems businesses include but are not limited to (1) rapidly changing technology; (2) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.
Contacts:
SurroMed, Inc. Noonan/Russo Communications, Inc.
August J. Moretti Ian McConnell, Ph.D
CFO and General Counsel Senior Account Executive
(650) 230-1564 (415) 677-4455 ext. 233
email: [email protected] email :[email protected]
Applied Biosystems
Media Investors
Lori Murray Peter Dworkin
(650) 638-6130 (650) 554-2479
[email protected] [email protected]